Medpace (NASDAQ:MEDP) Given New $362.00 Price Target at Robert W. Baird
Robert W. Baird lifted their target price on Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a research report on Monday.
Source link
Similar Posts
Northrim BanCorp: Rosy Earnings Outlook Appears Priced-In (NASDAQ:NRIM)
Northrim BanCorp: Rosy Earnings Outlook Appears Priced-In Source link
Top Clicks on Alpha Ideas this Week
Here are the most clicked items on Alpha Ideas this week: Young Bulls, Ageing Bears (AI) Avoiding Value Traps (AI) Sandur: 9 Years Left (AI) Mankind: Brand Factory (AI) Blackstone’s Best Investment Ever (Katusa) Boom in senior living homes (DH) Lookout notice against Fund Manager Devina Mehra (BW) The Club of Clueless CEOs (NDTV Profit)…
Zydus Lifesciences Secures Final USFDA Approval for Schizophrenia Drug, Shares Close Flat – Equitypandit
October 11, 2024October 11, 2024 Shares of Zydus Lifesciences Ltd. ended flat after hitting a day’s high of Rs 1,070.50 on 11th October, despite the firm announcing yesterday that it has received final approval from the United States Food and Drug Administration (USFDA) to manufacture paliperidone extended-release tablets in…
Gainers & Losers: Vodafone Idea among 7 big movers on Wednesday
Indian markets snapped a four-day losing streak on the final trading day of 2025, with metals, auto and financial stocks leading gains, while select stocks saw sharp moves on news and profit booking. Source link
10 Sensex stocks with up to 27% upside potential. Are you missing out? – Add to Cart
Analyst predictions offer more than just numbers — they provide insights into where the next wave of market opportunities could emerge. For investors scanning the Sensex for potential outperformers, the latest analyst consensus highlights several heavyweight names poised for strong returns in the coming year. According to Trendlyne data, multiple Sensex stocks show significant upside…
